Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Whelan

Podiatrist, Foot & Ankle Surgery Beloit, WI Doctor of Podiatric Medicine

NPI 1578983144 CMS profile 4013893

Beloit Health System INC, 1905 E. Huebbe Parkway, Beloit, WI 53511

Open in the dashboard

General payments

$50,868

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Whelan of Beloit, WI is reported in the CMS Open Payments database as having received $50,868 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,858 60
2024 General $2,846 32
2023 General $2,449 37
2022 General $5,655 52
2021 General $4,609 37
2020 General $334 6
2019 General $6,117 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Whelan
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to James Whelan were reported at $28,858. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year James Whelan Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $6,117 $389 $118–$1,406 $163
2020 $334 $191 $62–$691 $114
2021 $4,609 $329 $104–$1,341 $132
2022 $5,655 $419 $125–$1,611 $149
2023 $2,449 $377 $128–$1,164 $160
2024 $2,846 $394 $134–$1,168 $164
2025 $28,858 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $27,557 57 payments
  2. Stryker Corporation $11,390 108 payments
  3. Arthrex, Inc. $4,389 21 payments
  4. Orthofix Medical, Inc. $2,139 21 payments
  5. Access Pro Medical, LLC $1,910 2 payments
  6. RSW Medical Company, Inc. $804 2 payments
  7. Smith+Nephew, Inc. $745 31 payments
  8. Integra LifeSciences Corporation $449 5 payments
  9. Great Lakes Orthopedics $414 2 payments
  10. Organogenesis Inc. $358 10 payments
  11. Other $712 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $21,850 11 payments
  2. Travel and Lodging $14,572 71 payments
  3. Food and Beverage $9,682 192 payments
  4. Education $4,764 4 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM 1 $24,237 23 payments
  2. PROSTEP $3,461 15 payments
  3. Matriderm $1,910 2 payments
  4. Lapiplasty System Y $1,650 12 payments
  5. INFINITY $1,359 19 payments
  6. LAPIPLASTY SYSTEM Foot And Ankle $1,288 15 payments
  7. TrueLok $1,241 10 payments
  8. PRIME SERIES $1,016 8 payments
  9. SALVATION $948 13 payments
  10. TRAUMA $944 11 payments
  11. Other $11,848 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

319

Median for Podiatry: 160

Drug cost

$3,158

Median for Podiatry: $2,368

Branded share of claims

3.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 87 $1,550
Gabapentin Generic 54 $484
Ciclopirox Generic 19 $362
Oxycodone Hcl Generic 46 $214
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $187
Methylprednisolone Generic 42 $162
Meloxicam Generic 49 $116
Tramadol Hcl Generic 11 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$62,600

Medicare's payments for the services billed

Medicare patients

286

Average age 74

Services billed

1,120

173 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 51%
Diabetes 29%
Ischemic heart disease 24%
Chronic kidney disease 21%
Atrial fibrillation 17%
Depression 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record